Takeda Pharmaceutical Co ADR (TAK): Next-Year EPS Estimate 42.04%
As of 2026-06-04, Takeda Pharmaceutical Co ADR (TAK) has a next-year EPS growth estimate of 42.04%.
On 2026-06-03, analyst consensus for TAK's next-year EPS growth shifted from 42.09% to 42.04% — a negative change of 0.05 percentage points. The revised estimate has been sustained across 2 subsequent trading sessions. Current-year growth is projected at 13.90%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- EPS growth next year
- 42.04%
- EPS growth this year
- 13.90%
- EPS next quarter (est)
- $0.19
- Last price
- $15.45
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 42.04% | 13.90% | $0.19 | $15.45 |
| 2026-06-03 | 42.04% | 13.91% | $0.19 | $15.03 |
| 2026-06-02 | 42.09% | 12.23% | $0.19 | $15.18 |
| 2026-06-01 | 42.10% | 12.26% | $0.19 | $15.19 |
| 2026-05-31 | 41.45% | 12.73% | $0.19 | $15.96 |
| 2026-05-28 | 41.45% | 12.73% | $0.19 | $16.15 |
| 2026-05-27 | 39.42% | 19.27% | $0.19 | $16.15 |
| 2026-05-26 | 39.42% | 19.27% | $0.19 | $15.87 |
| 2026-05-25 | 39.42% | 19.27% | $0.19 | $16.25 |
| 2026-05-24 | 39.42% | 19.27% | $0.19 | $16.25 |
| 2026-05-21 | 35.02% | 23.15% | $0.19 | $16.48 |
| 2026-05-20 | 35.02% | 23.15% | $0.19 | $16.68 |
| 2026-05-19 | 35.02% | 23.15% | $0.19 | $16.58 |
| 2026-05-18 | 35.02% | 23.15% | $0.19 | $16.57 |
| 2026-05-17 | 35.02% | 23.15% | $0.19 | $16.61 |
| 2026-05-14 | 35.05% | 23.02% | $0.19 | $16.63 |
| 2026-05-13 | 29.98% | 25.40% | $0.19 | $16.55 |
| 2026-04-16 | 42.84% | 52.49% | $0.01 | $17.78 |
| 2026-04-15 | 42.83% | 52.54% | $0.01 | $17.85 |
| 2026-04-14 | 42.83% | 52.54% | $0.01 | $17.85 |
| 2026-04-13 | 48.53% | 52.98% | $0.01 | $17.82 |
| 2026-04-12 | 36.48% | 92.11% | $0.01 | $18.08 |
| 2026-04-10 | 48.53% | 52.98% | $0.01 | $18.11 |
| 2026-04-09 | 48.53% | 52.98% | $0.01 | $18.46 |
| 2026-04-08 | 48.57% | N/A | $0.01 | $18.66 |
| 2026-04-07 | 51.70% | N/A | $0.01 | $18.29 |
| 2026-04-06 | 51.70% | N/A | $0.01 | $18.29 |
| 2026-04-05 | 54.23% | N/A | $0.01 | $18.74 |
| 2026-04-03 | 51.70% | N/A | $0.01 | $18.29 |
| 2026-04-02 | 51.70% | N/A | $0.01 | $18.29 |
Recent News
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Takeda Pharmaceutical Co ADR's next-year EPS growth estimate?▾
As of 2026-06-04, Takeda Pharmaceutical Co ADR (TAK) has a next-year EPS growth estimate of 42.04%, based on analyst consensus.
When was the latest EPS estimate revision for TAK?▾
The most recent revision occurred on 2026-06-03, when analysts adjusted the next-year EPS growth estimate from 42.09% to 42.04%.
What sector and industry does Takeda Pharmaceutical Co ADR belong to?▾
Takeda Pharmaceutical Co ADR operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. TAK appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Takeda Pharmaceutical Co ADR (TAK) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports